Shareholders can obtain copies of Galmed's Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Clearmind’s Investor Relations Department at ...

Jefferies and Goldman Sachs & Co. LLC are acting as lead book-running managers for the offering. Mizuho is acting as bookrunner for the offering. Ladenburg Thalmann is acting as co-manager for the ...

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Eligibility: Stockholders must hold shares at the close of business on January 30, 2026 in order to receive the Warrant Dividends. Ratio: One (1) Warrant for every one (1) share of common stock held ...

Erasca intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents, and marketable securities, to fund the research and development of its product ...

Goldman Sachs & Co. LLC, Piper Sandler and Citigroup are acting as joint book-running managers for the proposed offering. BioAge intends to use the net proceeds from the proposed offering, together ...

Orphai Therapeutics Inc. (“Orphai”), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for patients with diseases of significant unmet need, today announced that ...

TXTM has entered a preliminary engagement with Deloitte, one of the world’s top five accounting and advisory firms, regarding an independent valuation of the Company’s enterprise, as part of its ...

Vitalic Health – powered by HFMA – is designed to bring together healthcare stakeholders to address issues negatively impacting affordability, health outcomes and industry financial sustainability.

A new national survey of frontline nurses highlights how health systems can strengthen patient access and throughput by aligning clinical expertise with systemwide insight. Conducted by Conduit Health ...

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the United States, announced the publication of new research in PLOS Pathogens identifying a novel mechanism that may trigger ...

FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review process; Company expects to submit updates to the BLA in February 2026 to support continued FDA ...